Sansure Immunological Technology Platform adopts advanced nanoparticle technology, protein labelling and modification technology, using high quality coloured latex and colloidal gold as tracers, and has developed a series of easy-to-use, highly sensitive and rapid detection products, covering SARS-CoV-2 antigen, SARS-CoV-2/InFluA/InFluB antigen, SARS-CoV-2 neutralizing antibody and other SARS-CoV-2 immunological reagents, to meet the needs of different scenarios such as home self-test, POCT and laboratory testing.
On the evening of April 26, Beijing time, the 142nd session of IPU Meeting of the Standing Committee on Peace and International Security was held online. Parliamentarians from more than 100 countries and representatives of some international organizations participated in the meeting and discussed the topic of “Global Cooperation in Overcoming the Pandemic”. Lizhong Dai,member of the National People’s Congress […]
Recently, Sansure Biotech has formally reached a strategic cooperation with Emergo by UL, a world-renowned medical device and IVD device market compliance agency, and signed a global strategic cooperation agreement. Jia Liu, Executive Dean of Sansure Biotech Life Science Institute, and Guiguo Gu, General Manager of Emergo by UL Asia Pacific, attended the signing ceremony and signed the cooperation agreement on […]
On February 18th, the Novel Coronavirus (SARS-CoV-2) and Influenza A/B Virus Nucleic Acid Diagnostic Kit (Immunochromatography) of Sansure Biotech obtained the EU CE certification, further enriching the respiratory product line of the company. At present, the cumulative number of confirmed cases of COVID-19 in the world has exceeded 100 million, which has brought unprecedented health, economic and social challenges to all […]